HLA-DR meets ERK

Blood

Volumn 115, Issue 25, 2010, Pages 5126-5127

  Hertlein, Erin ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CD74 ANTIGEN; HLA ANTIBODY; HLA DR ANTIGEN; HLA DR MONOCLONAL ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCLONAL ANTIBODY; OFATUMUMAB; RITUXIMAB; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CROSS LINKING; CYTOTOXICITY; EFFECTOR CELL; ENZYME ACTIVATION; GENE EXPRESSION; HLA SYSTEM; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; LYMPHOID CELL; LYMPHOMA; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TARGET CELL; TUMOR CELL;

EID: 77956544511     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-270256     Document Type: Note

References (3)

1. Stein R, Gupta P, Chen X, et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood. 2010;115(25):5180-5190.
2. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667-4679. (Pubitemid 36857719)
3. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 2002;99(4):1314-1319. (Pubitemid 34547086)